维普中文期刊产品整合服务
18篇 您的检索式:作者名="Melosky"
    题名 作者 年代 出处 被引量
1Supportive care treatments for toxicities of anti-egfr and other targeted agents显示文摘Melosky B 2012Curr Oncol2012,19,1:1
2Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies:Canadian rec- ommendations显示文摘Melosky B Burkes R Rayson D 2009Curr Oncol2009,16,1:1
3Review of EGFR TKIs in Metastatic NSCLC,Including Ongoing Trials显示文摘Melosky B 2014Front Oncol2014,4,:1
4Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignaneies: Canadian re- commendations显示文摘Melosky B Burkes R Rayson D 2009Curr Oneol2009,16,1:1
5Treatment algorithms for patients with metastatic non- small cell, non-squamous lung cancer显示文摘Melosky B 2014Front Oncol2014,4,:1
6Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations 显示文摘Melosky B Burkes R Rayson D 2009Curr Oncol2009,16,1:1
7The BC cancer agency experionce with gefitinib in advanced non -small cell lung cancer (NSCLC) 显示文摘Ho C Marray N Melosky 2004Proc Am Soc Clin Oncol2004,23,:1
8Review of EGFR TKIs in metastatic NSCLC, including ongoing trials 显示文摘Melosky B 2014Front Oncol2014,5,4:1
9The BC cancer agency experience with gefitinib in advanced non-small cell lung cancer (NSCLC) 显示文摘Ho C Murray N Melosky 2004Proc Am Soc Clin Oncol2004,23,:1
10Supportive care treatments for toxicities of anti- egfr and other targeted agents 显示文摘Melosky B 2012Curr Oncol2012,19,1:1
11The BC cancer agency experience with gefitinib in advanced non - small cell lung cancer (NSCLC) 显示文摘Ho C Murray N Melosky 2004Proc Am Soc Clin Oncol2004,23,:1
12Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIS 显示文摘Hirsh V Melosky B 2014Front Oncol2014,4,:1
13The BC cancer agency experience with gefitinib in advanced non-small cell lung cancer(NSCLC) 显示文摘Ho C Murray N Melosky B 2004Proc Am Soc Clin Oncol2004,22,14:1
14Retrospective practice review of treatment of metastatic non-small cell lung cancer with second line erlotinib 显示文摘MELOSKY B AGULNIK J ASSI H 2008Curr Oncol2008,15,6:1
15Cutaneous reactions to anticancer agents targeting the epidermal growth material protected by copright factor receptor:A dermatology-oncology perspective显示文摘Lacouture M Melosky B 2007Skin Therapy Letter2007,12,:1
16Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal maligancies:Canadian recommendations显示文摘Melosky B Burkes R Rayson D 2009Current Oncology2009,16,1:1
17Erlotinib ordocetaxel for second-line treatment of non-small cell lung can-cer: a real-world cost-effectiveness analysis显示文摘Cromwell I van der Hoek K Melosky B 2011J Thorac On-col2011,6,12:1
18Management of skin rash during EGFR targeted monoclonal antibody treatment for gastrointestinal malignancies:Canadian recommendations显示文摘Melosky Burkes R Rayson D 2009Current Oncology2009,16,1:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费